date:Sep 17, 2012
t recovery and energy. InFat is marketed by Advanced Lipids, a joint venture of AAK and Enzymotec. The study was the first testing the positive effect of a commercial term-infant formula containing beta-palmitate on Chinese infants' well-being. It was conducted by Professor Chen Yu-Ming, the principle investigator at Sun Yat-Sen University and in collaboration with Enzymotec.
The clinical trials plan represents Enzymotec's ongoing commitment to explore the special characteristics of human milk